COMMUNIQUÉS West-GlobeNewswire

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
29/01/2026
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE [...]
XTL Update on Recent Developments
29/01/2026
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ Company ” or “ XTL ”), announced that it is working diligently to close the acquisition of 85% of the [...]
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
29/01/2026
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its [...]
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
29/01/2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
30/01/2026
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
29/01/2026
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of [...]
CareMed Has Been Selected as a National Specialty Pharmacy Provider for Exdensur (depemokimab-ulaa)
29/01/2026
NEW HYDE PARK, N.Y., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by GSK for Exdensur (depemokimab), indicated for the add-on maintenance [...]
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
29/01/2026
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease [...]
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
29/01/2026
WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that the current time- and individual performance-based long-term stock incentive [...]
Ardena completes divestment of its Södertälje drug substance site in Sweden to Nanologica
29/01/2026
Ghent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance ( [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
29/01/2026
Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the [...]
AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
29/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN AVIS D'AUTORISATION POUR UN BREVET AMÉRICAIN COUVRANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT CETTE DÉCISION FAVORABLE DE L’ [...]
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
29/01/2026
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA PATENT OFFICE [...]
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
29/01/2026
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal [...]
JenaValve Appoints John Molyneux to Vice President of Operations
29/01/2026
IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John Molyneux to Vice [...]
Governor Desantis Appoints Dr. Chadwick Marshall to Serve on Florida Board of Dentistry
29/01/2026
IRVING, Texas and FORT WALTON BEACH, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) congratulates its surgeon partner Chadwick J. Marshall , DMD, MD, who was recently appointed by Governor [...]
Alira Health Opens the Registration for the Third Edition of the Global Payer Forum
29/01/2026
An Annual Global Event Examining the Key Trends Reshaping Access to Healthcare Innovation FRAMINGHAM, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alira Health today opens the registration for the third edition of its [...]
Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer
29/01/2026
Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer Largest real-world, blinded, multi-site validation of AI molecular profiling from routine diagnostic [...]
Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy
29/01/2026
Former CEO Dr. Bryan Kim will retain current role as CEO of Verismo Therapeutics FORT LEE, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Group and a fully [...]

Pages